CJC-1295 vs Ipamorelin
A factual side-by-side from public databases — chemical identity, literature volume, and attributed independent-test coverage. Not a recommendation; we don't rank one above the other.
CJC-1295 is described as a long-acting growth-hormone-releasing hormone (GHRH) analog. Clinical research in healthy adults reported sustained, dose-dependent increases in circulating growth hormone (GH) and insulin-like growth factor I (IGF-I) after subcutaneous administration, with effects persisting for days and no serious adverse reactions reported in the studied cohorts.
Ipamorelin is described in the provided literature as a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) with growth hormone (GH)-releasing properties. Reviews in orthopaedics/sports medicine discuss ipamorelin as a “growth hormone secretagogue” (GH/IGF-1 signaling–associated peptide) while noting that clinical evidence for musculoskeletal uses is limited.
| CJC-1295 | Ipamorelin | |
|---|---|---|
| Family | GHRH analogs | Ghrelin / GH secretagogues |
| Research goals | GH axis support | GH axis support |
| Amino acids | — | — |
| Molecular formula | C165H269N47O46 | C38H49N9O5 |
| Molecular weight | 3647.2 g/mol | 711.9 g/mol |
| CAS number | 446262-90-4 | 170851-70-4 |
| Approx. half-life | — | — |
| Regulatory status | Research only | Research only |
| WADA status | — | — |
| Evidence maturity | — | — |
| Research references | 8 | 8 |
| Vendors independently tested | 16 | 60 |
| Best test score (Finnrick) | 4.9 | 9.9 |